This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Epigenetic editing startup Chroma Medicine is merging ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio. nChroma will develop Chroma’s epigenetic editing platform and Nvelop’s viruslike delivery platform. The new firm has raised $75 ...
Two biotech companies, Chroma Medicine and Nvelop Therapeutics, have merged to form nChroma Bio, a new company that combines epigenetic editing capabilities with in vivo delivery technologies.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Jeff Walsh, the newly formed ...
Company's non-viral DLVR-M platform enables humanized particles for delivery of a wide range of diverse cargoes to a variety of different cell types. CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 22, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results